Tetra Bio Pharma (TSXV: TBP) has strengthened its product pipeline as of this morning, providing the company with new potential drug candidates following the approval of Caumz and Qixleef for marketing by the appropriate health agencies. The company has signed a co-development agreement with that of MAKScientific to enable the access to novel patented drug molecules.
The definitive co-development agreement will enable Tetra to have access to new patented molecules with CB1 and CB2 agonist or antagonist profiles. The access to the molecules will enable Tetra to remain focused on its goal of utilizing the endocannabinoid system to provide health care solutions.
MAKScientific has developed a pipeline of small molecule drugs that interact with the CB1 and CB2 receptors within the endocaannabinoid system. Under the agreement, MAKScientific will continue to develop new molecules that will then be screened by Tetra for the potential to use the molecules to combat pain, cancer, inflammation as well as other potential targets of interest.
A successful Biopharmaceutical company requires a pipeline of patent protected molecules that can become its next generation therapeutics. Patent protection is one of the most important aspects to safeguarding the company’s assets and its shareholders investments.
Dr. Guy Chamberland, CEO and CRO of Tetra
Tetra Bio Pharma last traded at $0.36 on the TSX Venture.
Information for this briefing was found via Sedar and Tetra Bio-Pharma Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
